QT prolongation as a significant cardiovascular complication in cancer therapy

Main Article Content

S. M. Kozhukhov
S. I. Deyak
O. Ye. Bazyka
N. V. Dovganich
O. Ya. Yarynkina
N. V. Tkhor


The widespread introduction of new anticancer drugs and treatment technologies has contributed to an increase in the survival rate of cancer patients. At the same time, the development of cardiovascular complications in the setting of anticancer treatment often leads to a decrease in the quality of life and worse prognosis.
One of the manifestations of cardiovascular complications during cancer treatment is QT prolongation with various cardiac arrhythmias.
The article is based on the analysis of randomized clinical trials and meta-analyses, and the recommendations of the European Society of Cardiology on Cardio-Oncology. The review describes the risk factors and classification of QT prolongation caused by anticancer therapy.The main groups of anticancer drugs that induce changes in the QT interval are analyzed. The methods and frequency of examination of cancer patients with various pathological conditions and comorbidities that can lead to QT prolongation during and after cancer treatment are considered.
The review is devoted to the analysis of changes in the QT interval and clinical application of decision-making algorithms to minimize cardiotoxicity in order to improve the effectiveness of anticancer treatment.

Article Details


cardiotoxicity, QT interval, QT prolongation, risk factors, chemotherapy, rhythm disturbances


Bulletin of the National Cancer Registry of Ukraine [Byuletenʹ Natsionalʹnoho Kantser-reyestru Ukrayiny]. Kyiv, 2023;24:145. http://www.ncru.inf.ua/publications/BULL_24/index.htm

Kozhukhov SM, Smolanka II, Kryachok IA, Dovganich NV, Ligirda OF. Development of cardio-oncology in Ukraine: rationale, organization and implementation in clinical practice. Ukr Cardiol J. 2019;4:120-8. HTTPS://DOI.ORG/https://doi.org/10.31928/1608-635X-2019.4.120128

Afifi AM, Saad AM, Al-Husseini MJ, et al. Causes of death after breast cancer diagnosis: A US population-based analysis. Cancer. 2020 Apr 1;126(7):1559-67. HTTPS://DOI.ORG/10.1002/cncr.32648

Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: Executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Heart Rhythm. 2018;15:e190–e252. HTTPS://DOI.ORG/10.1161/CIR.0000000000000548

Barac A, Murtagh G, Carver JR, et al. Cardiovascular health of patients with cancer and cancer survivors: a roadmap to the next level. J Am Coll Cardiol. 2015;65(25):2739-46. HTTPS://DOI.ORG/10.1016/j.jacc.2015.04.059

Campia U, Moslehi J, Amiri-Kordestani L, et al. On behalf of the American Heart Association Council on Peripheral Vascular Disease; Council on Arteriosclerosis, Thrombosis and Vascular Biology; and Council on Cardiovascular and Stroke Nursing Cardio-Oncology: Vascular and Metabolic Perspectives A Scientific Statement From the American Heart Association. Circulation. 2019;139:e579-e602. HTTPS://DOI.ORG/10.1161/CIR.0000000000000641

Cortes JE, Saglio G, Kantarjian H, et al. Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial. J Clin Oncol. 2016;34(20):2333-40. HTTPS://DOI.ORG/10.1200/JCO.2015.64.8899

Cuni R, Parrini I, Asteggiano R, et al. Targeted Cancer Therapies and QT Interval Prolongation: Unveiling the Mechanisms Underlying Arrhythmic Complications and the Need for Risk Stratification Strategies. Clin Drug Investig. 2017;37:121-34. HTTPS://DOI.ORG/10.1007/s40261-016-0460-5

Curigliano G, Lenihan D, Fradley M, et al. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. Annals of Oncology. 2020;31(2):171-90. HTTPS://DOI.ORG/10.1016/j.annonc.2019.10.023

Giraud EL, Ferrier KRM, Lankheet NAG, et al. The QT interval prolongation potential of anticancer and supportive drugs: a comprehensive overview. Lancet Oncol. 2022 Sep;23(9):e406-e415. HTTPS://DOI.ORG/10.1016/S1470-2045(22)00221-2

Finn RS, Martin M, Rugo HS, et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med 2016;375(20):1925-36. HTTPS://DOI.ORG/10.1056/NEJMoa1607303

Fradley MG, Beckie TM, Brown SA, et al. Recognition, prevention, and management of arrhythmias and autonomic disorders in cardio-oncology: a scientific statement from the American Heart Association. Circulation. 2021;144(3):e41–e55. HTTPS://DOI.ORG/10.1161/CIR.0000000000000986

Fradley MG, Moslehi J. QT prolongation and oncology drug development. Card Electrophysiol Clin. 2015;7(2):341-55. HTTPS://DOI.ORG/10.1016/j.ccep.2015.03.013

Hortobagyi GN, Stemmer SM, Burris HA, et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med. 2016;375(18):1738-48. HTTPS://DOI.ORG/10.1056/NEJMoa1609709

Jain V, Bahia J, Mohebtash M, Barac A. Cardiovascular Complications Associated With Novel Cancer Immunotherapies. Curr Treat Options Cardiovasc Med. 2017;19:36. HTTPS://DOI.ORG/10.1007/s11936-017-0532-8

Johnson DB, Balko JM, Compton ML, et al. Fulminant Myocarditis with Combination Immune Checkpoint Blockade. New Engl J Med. 2016;375:1749-55. HTTPS://DOI.ORG/10.1056/NEJMoa1609214

Kim PY, Irizarry-Caro JA, Ramesh T, et al. How to Diagnose and Manage QT Prolongation in Cancer Patients. JACC CardioOncol. 2021 Mar 16;3(1):145-9. https://doi.org/10.1016/j.jaccao.2021.01.002. PMID: 34396315

Kourek C, Touloupaki M, Rempakos A, et al. Cardioprotective Strategies from Cardiotoxicity in Cancer Patients: A Comprehensive Review. J Cardiovasc Dev Dis. 2022 Aug 11;9(8):259. https://doi.org/10.3390/jcdd9080259

Kozhukhov SM, Dovganych NV, Smolanka II, et al. Cardiotoxity Risk Prediction in Breast Cancer Patients. Problemy Radiatsiinoi Medytsyny ta Radiobiolohii. 2021;26:498-512. HTTPS://DOI.ORG/10.33145/2304-8336-2021-26-498-512 PMID: 34965569.

Kozhukhov S, Dovganych N. Cardio-Oncology Educational Program: National Survey as the First Step to Start. Frontiers in Cardiovascular Medicine, Aug. 2021;8:697240. HTTPS://DOI.ORG/10.3389/fcvm.2021.697240

Lancellotti P, Suter TM, Lopez-Fernandez T, et al. Cardio-Oncology Services: rationale, organization, and implementation: A report from the ESC Cardio-Oncology council. Eur. Heart J. 2018;40(22):1756-63. HTTPS://DOI.ORG/10.1093/eurheartj/ehy453

Lenihan DJ, Oliva S, Chow EJ, Cardinale D. Cardiac toxicity in cancer survivors. Cancer. 2013;119(11):2131-42. HTTPS://DOI.ORG/10.1002/cncr.28061

Lyon AR, López-Fernández T, Couch LS, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS): Developed by the task force on cardio-oncology of the European Society of Cardiology (ESC). Eur Heart J. 2022;43(41):4229-361. https://doi.org/10.1093/eurheartj/ehac244

Pareek N, Cevallos J, Moliner P, et al. Activity and outcomes of a cardio-oncology service in the United Kingdom – a five-year experience. Eur. J. Heart Fail. 2018;20:1721-31. https://doi.org/10.1002/ejhf.1292

Parent S, Pituskin E, Paterson DI. The cardio-oncology program: a multidisciplinary approach to the care of cancer patients with cardiovascular disease. Can J Cardiol. 2016;32: 847-51. HTTPS://DOI.ORG/10.1016/j.cjca.2016.04.014

Porta-Sánchez A, Gilbert C, Spears D, et al. Incidence, Diagnosis, and Management of QT Prolongation Induced by Cancer Therapies: A Systematic Review. J Am Heart Assoc. 2017 Dec 7;6(12):e007724. HTTPS://DOI.ORG/10.1161/JAHA.117.007724

Priori SG, Blomstrom-Lundqvist C, Mazzanti A, et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: the Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Eur Heart J 2015;36(41):2793–867. https://doi.org/10.1093/eurheartj/ehv316

Rochette L., Guenancia C., Gudjoncik A. et al. Anthracyclines/ trastuzumab: new aspects of cardiotoxicity and molecular mechanisms. Trends. Pharmacol. Sci. 2015;36: 326–348. HTTPS://DOI.ORG/10.1016/j.tips.2015.03.005

Tamargo J., Caballero R., Delpon E. Cancer chemotherapy and cardiac arrhythmias: a review. Drug Saf 2015;38(2):129–52. PMID: 25577497. HTTPS://DOI.ORG/10.1007/s40264-014-0258-4

TeBay C., Hill A., Windley, M. Metabolic and electrolyte abnormalities as risk factorsin drug‑induced long QT syndrome. Biophys 2022;14:353–367. https://doi.org/10.1007/s12551-022-00929-7

Tisdale JE, Chung MK, Campbell KB. et al. Drug-induced arrhythmias: a scientific statement from the American Heart Association. Circulation 2020;142:E214–E233. HTTPS://DOI.ORG/10.1161/CIR.0000000000000905

Tripathy D, Im SA, Colleoni M. Et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet Oncol. 2018 Jul;19(7):904-915. HTTPS://DOI.ORG/10.1016/S1470-2045(18)30292-4 PMID: 29804902.

Wang D.Y., Okoye G.D., Neilan T.G. et al. Cardiovascular toxicities associated with cancer immunotherapies. Curr. Cardiol. Rep. 2017;(19):21. HTTPS://DOI.ORG/10.1007/s11886-017-0835-0

Ward M., Harnett J., Bell T.J., Mardekian J. Risk Factors of QTc Prolongation in Women With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2-negative Metastatic Breast Cancer: A Retrospective Analysis of Health Care Claims Data Clinical Therapeutics. 2019;41(3):494-504. HTTPS://DOI.ORG/10.1016/j.clinthera.2019.01.012

Zamorano J. L., Lancellotti P., Rodriguez Munoz D. et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. Eur Heart J 2016;37(36): 2768–801. HTTPS://DOI.ORG/10.1093/eurheartj/ehw211. PMID: 27567406.

Zeppenfeld K, Tfelt-Hansen J, de Riva M. et al. 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J 2022;43(40):3997–4126. HTTPS://DOI.ORG/10.1093/eurheartj/ehac262

Zhang Y, Post WS, Blasco-Colme-nares E, et al. Electrocardiographic QT interval and mortality: a meta-analysis. Epidemiology 2011;22(5):660–70. HTTPS://DOI.ORG/10.1097/EDE.0b013e318225768b

Most read articles by the same author(s)